Platform Partnerships Alaunos’ non-viral Sleeping Beauty gene transfer platform for TCR therapies offers a licensing or collaboration pathway to scale manufacturing, broaden the pipeline, and access a robust mutation hotspot TCR library, enabling partners to accelerate solid-tumor programs.

Discovery Platform The hunTR TCR discovery platform presents a clear opportunity for pharma to license discovery rights or co-develop novel TCRs targeting high-need solid-tumor mutations, potentially accelerating program timelines.

Clinical Stage Partnering As a clinical-stage cell therapy company, Alaunos is well positioned for strategic collaborations that share development risk, access oncology expertise, and monetize its TCR library through licensing or joint-venture deals.

Boston Ecosystem Based in Boston, the company benefits from a dense biotech ecosystem, enabling rapid engagement with contract research organizations, manufacturing partners, and translational science collaborators to accelerate trials.

Financial Signals Current revenue and funding activity indicate a readiness to pursue strategic partnerships to advance clinical programs, with opportunities for milestone-driven collaborations and co-development funding.